WASHINGTON — The Pentagon has resumed a mandatory testosterone screening programme for male US service members aged 30 and older, reviving a policy that defence officials say is aimed at improving health, performance and military readiness.
The revised clinical guidance, released late Thursday, requires testosterone testing during periodic health assessments and annual physical examinations for male troops in that age group. Younger male service members may also be tested if they request it or if doctors determine that screening is clinically appropriate.
The policy follows an earlier version that was temporarily withdrawn in early September to allow updates. Defence Secretary Pete Hegseth first announced the initiative in July, saying screening for testosterone deficiency would help troops perform at their “absolute best.”
The Pentagon says the programme is intended to identify and manage testosterone deficiency through standardised screening and treatment procedures. Any testosterone replacement therapy would be voluntary and subject to medical evaluation.
The current guidance applies only to male service members. The Pentagon said separate guidance for female troops may be issued later, but no female-specific testosterone testing programme has been announced.
The move has drawn questions from medical experts, who say routine testosterone screening is not generally recommended for men without symptoms. The Associated Press reported that many current medical standards advise testing only when patients show symptoms consistent with low testosterone and when low levels are confirmed by laboratory testing.
Experts have also warned that unnecessary testosterone treatment can carry risks, including infertility and other health complications. Reuters reported that medical professionals have expressed concern that broad screening could lead to overdiagnosis or treatment that may not be needed.
The policy comes amid growing public interest in testosterone treatment, often promoted by men’s health influencers as a way to increase energy, muscle mass and vitality. But medical experts say evidence for broad anti-ageing or performance benefits remains limited.
The Food and Drug Administration has changed some testosterone labelling requirements in recent years, including removing a boxed warning about cardiovascular risks, but FDA-approved testosterone treatments remain limited to men with medically diagnosed deficiencies.
For the Pentagon, the screening programme is part of a broader push under Hegseth to emphasise physical fitness, readiness and performance standards across the armed forces. For critics, the central question is whether mandatory testing for asymptomatic troops is medically justified.
The revised guidance takes effect immediately, but debate over the programme is likely to continue as military doctors begin applying it across the force.



















